Definium Therapeutics Q1 Net Loss $(77.1)M; Operating Expenses Up
Definium Therapeutics reported a net loss of $(77.1) million for the first quarter of 2026, a significant increase from $(23.3) million in the same period last year, primarily driven by higher operating expenses, including a substantial increase in research and development costs and a negative change in the fair value of financing warrants. The company, which recently changed its name from Mind Medicine (MindMed) Inc., continues to advance its lead product candidates, DT120 and DT402, through clinical trials for brain health disorders. Despite the increased loss, Definium Therapeutics maintains a strong liquidity position with $262.5 million in cash and cash equivalents, which management believes is sufficient to fund operations for at least the next twelve months.
Key Highlights
- Net loss increased to $(77.1) million in Q1 2026 from $(23.3) million in Q1 2025.
- Total operating expenses rose to $59.2 million in Q1 2026 from $32.2 million in Q1 2025.
- Research and development expenses increased to $41.5 million in Q1 2026 from $23.4 million in Q1 2025.
- Net loss per common share (basic) was $(0.71) in Q1 2026, compared to $(0.27) in Q1 2025.
- Cash and cash equivalents stood at $262.5 million as of March 31, 2026.
- The company changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc. on January 9, 2026.
- Management believes it has sufficient cash to fund operations for at least the next twelve months.
- A $(20.0) million expense was recorded for the change in fair value of 2022 USD Financing Warrants in Q1 2026.
Price Impact
More from DFTX